I used to follow LEXG tangentially back in the days when I owned EXEL. Back then, the two companies were similar, but they have gone in different directions.
Speaking of EXEL… their recent CC to describe the changes to their collaboration with GSK was as obfuscating as ever. There is no way for investors to figure out what EXEL is really worth, and hence I’m steering clear of them despite their impressive progress in the clinic.
News 
Market Data 
Discover 
AI
